Holen Sie sich die Stockscreener-App
12.03
0.33%
0.04
Amarin Corp Adr Aktie (AMRN) Neueste Nachrichten
EDIT Set to Begin First-in-Human Study in Hypercholesterolemia - Zacks Investment Research
Here's Why You Should Add LPCN Stock to Your Portfolio Now - Zacks Investment Research
ETON Stock Surges 108% in Six Months: Here's What You Need to Know - Zacks Investment Research
Amarin Corporation plc (AMRN) Options Chain - Yahoo! Finance Canada
Amarin Corporation plc (AMRN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Merck's Tulisokibart Meets Endpoints in Hidradenitis Suppurativa Study - Zacks Investment Research
Amarin Stock Price Forecast. Should You Buy AMRN? - StockInvest.us
Amarin Corporation plc (AMRN) Options ChainYahoo Finance - Yahoo! Finance Canada
Amarin Corporation plc (AMRN) Options ChainYahoo Finance - Yahoo! Finance Canada
Why Is Tango Therapeutics (TNGX) Down 6.2% Since Last Earnings Report? - Zacks Investment Research
Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Amarin Highlights New ESC 2026 Data and Guideline Support Reinforcing Evidence for Icosapent Ethyl - Quiver Quantitative
Amarin analysis links Vascepa adherence to greater, longer-lasting heart benefits (AMRN:NASDAQ) - Seeking Alpha
Heart treatment linked to ~30% fewer major events; benefits may persist after stopping - Stock Titan
Amarin (NASDAQ: AMRN) sees Sarissa report 25.7M+ shares - Stock Titan
Amarin Announces REDUCE-IT-Related Presentations at ESC Congress 2026 in Munich - Quiver Quantitative
Five abstracts from an 8,179-patient study are set for the 2026 heart congress - Stock Titan
Amarin (AMRN) Holds Near $14.15 as Bulls Defend Key Support ZoneMomentum Stock Picks - careplusvn.com
Amarin Corporation Plc Sponsored ADR Revenue Breakdown – LSX:A41557 - TradingView
Earnings call transcript: Amarin Q2 2026 revenue falls, but cash flow improves - Investing.com
Amarin Corp PLC (AMRN) Q2 2026 Earnings Call Highlights: Strategic Growth Amidst Revenue Challenges - Yahoo Finance
Amarin's Q2 Earnings Beat Estimates, Revenues Fall Short - TradingView
Amarin Corporation PLC reports results for the quarter ended June 30Earnings Summary - tradingview.com
Amarin's Q2 Earnings Beat Estimates, Revenues Fall Short - Yahoo Finance
Amarin Corporation Plc Sponsored ADR Revenue Breakdown – FWB:EH3 - TradingView
Amarin Corporation PLC expected to post a loss of 1 cent a shareEarnings Preview - TradingView
Amarin CorpADR (AMRN) Fundamental & Financial Data - Stocktwits
AMRN: Amarin CorpADR Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Bears are Losing Control Over Amarin (AMRN), Here's Why It's a 'Buy' Now - Yahoo Finance
EU Approves Expanded Use of ABBV's Tepkinly in Follicular Lymphoma - TradingView
Amarin: The Market Is Pricing A 55% Chance Of A Sale That Isn't Coming (NASDAQ:AMRN) - Seeking Alpha
AMRNAmarin Corp ADR Options - Finviz
Collegium Pharmaceutical Stock Gains 12% in Three Months: Here's Why - TradingView
Amarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA® (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape - Barchart.com
Amarin Corporation Plc Sponsored ADR Actuals & Estimates (NASDAQ:AMRN) - TradingView
EH3 Forecast — Price Target — Prediction for 2027 - TradingView
EH3 Forecast — Price Target — Prediction for 2027 - TradingView
Here's Why You Should Add ANIX Stock to Your Portfolio Now - TradingView
Reasons Why Investors Should Consider Betting on Indivior Stock - TradingView
Net income before discontinued operations of Amarin Corporation Plc Sponsored ADR – DUS:EH3 - TradingView
Price to book ratio of Amarin Corporation Plc Sponsored ADR – DUS:EH3 - TradingView
Non-operating income (total) of Amarin Corporation Plc Sponsored ADR – DUS:EH3 - TradingView
Current ratio of Amarin Corporation Plc Sponsored ADR – DUS:EH3 - TradingView
Free cash flow per share of Amarin Corporation Plc Sponsored ADR – DUS:EH3 - TradingView
Diluted earnings per share (diluted EPS) of Amarin Corporation Plc Sponsored ADR – DUS:EH3 - TradingView
Amarin Corporation Plc Sponsored ADR Revenue Breakdown – DUS:EH3 - TradingView
Is Amarin (AMRN) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma - Benzinga
Amarin dealt blow as Supreme Court upholds 'skinny labels' for generics - Seeking Alpha
AMRNAmarin Corp ADR Short Interest - Finviz
3.31%
6.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):